Physician profile
Nira Madisi
NPI 1952531899
$23,289.07
in general payments reported to CMS, 2019-2025
23 companies · $21K in 2025
The $21K reported for 2025 was more than what 93% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $632 · 2020: $250 · 2022: $570 · 2023: $568 · 2024: $459 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $2,344 · Travel and Lodging: $2,277 · Education: $16.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,200.00 |
| Food and Beverage | $2,343.91 |
| Travel and Lodging | $2,276.98 |
| Education | $16.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $21,086.23 | 2019-2025 | Evenity, Xgeva, Prolia |
| Medtronic, INC. | $422.59 | 2022-2024 | Minimed 780g |
| Lilly USA, LLC | $381.76 | 2019-2025 | Zepbound, Mounjaro |
| Sanofi-Aventis U.S. LLC | $229.87 | 2019-2024 | |
| Novo Nordisk INC | $176.03 | 2019-2025 | Ozempic, Rybelsus |
| Pulmonx Corporation | $147.97 | 2022 | |
| Halozyme INC | $126.00 | 2023 | |
| Horizon Therapeutics Plc | $122.88 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $106.80 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.26 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $75.48 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Mannkind Corporation | $65.83 | 2020-2024 | |
| Insulet Corporation | $55.47 | 2019 | |
| Becton, Dickinson and Company | $36.09 | 2019 | |
| Corcept Therapeutics | $35.32 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $24.28 | 2019 | |
| Xeris Pharmaceuticals, INC. | $21.88 | 2020 | |
| Shire North American Group INC | $17.40 | 2019 | |
| Tolmar, INC. | $17.12 | 2024 | |
| Abbvie INC. | $15.00 | 2019 | |
| Abbott Laboratories | $14.12 | 2019 | |
| Merck Sharp & Dohme LLC | $13.25 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nira Madisi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.